Author:
Kan Liyen K.,Drill Matthew,Jayakrishnan Padmakrishnan C.,Sequeira Richard P.,Galea Emily,Todaro Marian,Sanfilippo Paul G.,Hunn Martin,Williams David A.,O’Brien Terence J.,Drummond Katharine J.,Monif Mastura
Abstract
AbstractGlioblastomas are highly aggressive and deadly brain tumours, with a median survival time of 14–18 months post-diagnosis. Current treatment modalities are limited and only modestly increase survival time. Effective therapeutic alternatives are urgently needed. The purinergic P2X7 receptor (P2X7R) is activated within the glioblastoma microenvironment and evidence suggests it contributes to tumour growth. Studies have implicated P2X7R involvement in a range of neoplasms, including glioblastomas, although the roles of P2X7R in the tumour milieu remain unclear. Here, we report a trophic, tumour-promoting role of P2X7R activation in both patient-derived primary glioblastoma cultures and the U251 human glioblastoma cell line, and demonstrate its inhibition reduces tumour growth in vitro. Primary glioblastoma and U251 cell cultures were treated with the specific P2X7R antagonist, AZ10606120 (AZ), for 72 h. The effects of AZ treatment were also compared to cells treated with the current first-line chemotherapeutic drug, temozolomide (TMZ), and a combination of both AZ and TMZ. P2X7R antagonism by AZ significantly depleted glioblastoma cell numbers compared to untreated cells, in both primary glioblastoma and U251 cultures. Notably, AZ treatment was more effective at tumour cell killing than TMZ. No synergistic effect between AZ and TMZ was observed. AZ treatment also significantly increased lactate dehydrogenase release in primary glioblastoma cultures, suggesting AZ-induced cellular cytotoxicity. Our results reveal a trophic role of P2X7R in glioblastoma. Importantly, these data highlight the potential for P2X7R inhibition as a novel and effective alternative therapeutic approach for patients with lethal glioblastomas.
Funder
National Health and Medical Research Council
Australian Government
Publisher
Springer Science and Business Media LLC
Reference64 articles.
1. Hanif, F., Muzaffar, K., Perveen, K., Malhi, S. M. & Simjee, S. U. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pacific J. Cancer Prev. APJCP 18, 3–9 (2017).
2. Tamimi, A. F. & Juweid, M. in Glioblastoma (ed S. De Vleeschouwer) (Codon Publications Copyright: The Authors., 2017).
3. Tan, A. C. et al. Management of glioblastoma: State of the art and future directions. CA Cancer J. Clin. 70(4), 299–312. https://doi.org/10.3322/caac.21613 (2020).
4. Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466. https://doi.org/10.1016/s1470-2045(09)70025-7 (2009).
5. Chamberlain, M. C. Temozolomide: Therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev. Neurother. 10, 1537–1544. https://doi.org/10.1586/ern.10.32 (2010).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献